Incyte Enters Asset Purchase Agreement With Morphosys; Gains Exclusive Global Development And Commercialization Rights To Tafasitamab (Monjuvi)

Author: Benzinga Newsdesk | February 05, 2024 05:48pm

Incyte gains exclusive global rights for tafasitamab, a humanized Fc-modifiedCD19-targeting immunotherapy marketed in the U.S. as Monjuvi® (tafasitamab-cxix) and outside of the U.S. as Minjuvi® (tafasitamab). Under the terms of the new agreement, MorphoSys will receive a payment of $25 million from Incyte and Incyte will gain global development and commercialization rights for tafasitamab. Incyte will now recognize revenue and cost for all U.S. commercialization and clinical development and MorphoSys will no longer be eligible to receive future milestone, profit split and royalty payments. The agreement is effective immediately.

Posted In: INCY MOR